Novel drug delivery approaches (e.g., nanoparticles and liposomes) are also being utilised to co-deliver agents targeting CXCR4 and chemotherapy directly to the tumour site, which ameliorates systemic toxicities and increases efficacy [25]. The gene discussed is CXCR4; the disease is neoplasm.